Overview
- Published March 13 in Neuron, the work from Liang Zhang’s team links a high-altitude Retsat mutation (Q247R) to stronger myelination and resilience in neonatal mice under severe hypoxia.
- In adult myelin-injury models, mice carrying the variant showed faster, more complete remyelination and increased numbers of mature oligodendrocytes.
- Mechanistically, the mutation boosts neuronal production of ATDR, which is converted to a dihydroretinoic acid that signals to oligodendrocyte progenitors via RXR-γ in a neuron-to-glia pathway.
- Administered ATDR acted as a prodrug that the authors report crosses the blood–brain barrier, reduced clinical severity and improved motor function in an MS-like mouse model, and promoted repair across multiple injury paradigms.
- Experts highlight promise for regeneration-focused therapies while stressing that dosing, safety, pharmacokinetics, and feasibility in humans remain unresolved.